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represent targetable pathways with clinically-available novel
therapeutics.
Sirolimus resulted in partial downregulation of proliferation
and cytotoxicity pathways. However, many genes and
networks were shared between the Sirolimus and GvHD
cohorts, indicating inadequately controlled activation. These
prominently included upregulation of the FOXM1 and IRF8
transcription factors, involved in cell cycle progression and
interferon signaling (P < .01), respectively. Both GvHD and
Sirolimus also demonstrated upregulation of the CD28, CCR5,
IL-12 and IL-17 pathways (P < .05), all targetable with FDA-
approved therapeutics (CTLA4-Ig, maraviroc, ustekinumab).
Conclusions: This is theﬁrst description of the primateGvHD
transcriptome. This network approach has identiﬁed previ-
ously unappreciated genes and pathways associated with
GvHD, for which several novel therapeutic strategies are
immediately available for pre-clinical and clinical evaluation.
Figure 1. The Primate GvHD Transcriptome: (A) Principal Component Analysis
(PCA) reveals that maximal variation between the arrays was determined by
the experimental cohort. (B) Differentially Expressed (DE) Genes Compared to
Healthy Controls (HC). Left: Shown Are numbers of Up- (red) and Down- (blue)
regulated genes in Auto, Sirolimus, and GvHD cohorts compared to HC. Right:
Venn Diagrams showing overlap of DE genes between the three cohorts. (C)
Ingenuity Pathway Analysis depicting gene networks differentially regulated
during GvHD. Shown are representative networks showing cell cycle (left) and
inﬂammatory response genes (right).441
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Introduction: Graft-versus-host disease (GVHD) is on of the
leading complication of allogeneic hematopoietic stem cell
transplantation (HSCT) causing signiﬁcant morbidity and
mortality. CD4+ T-cells play a critical role inmediating GVHD,
and much effort has been devoted to studying the effect of
CD4+ T-cells during the pathophysiology process of GVHD.
Even though just accounting for 5% of the total CD4+ T-cell
population, the most promising candidates are naturally
occurring CD4+CD25+ regulatory T cells (Tregs), which are on
of the regulators of immune responses. TH17 is a newly
identiﬁed T-cell lineage that secretes IL-17, a proin-
ﬂammatory cytokine. However, the functional role of TH17
cells in the development of GVHD has not been well char-
acterized in humans. The aim of our study was to charac-
terize the expression of Treg (FOXP3) and TH17-related (RORgt)
genes in peripheral blood of patients undergoing HSCT and
correlate them with the development of GVHD in HLA
identical allogeneic HSCT.
Patients and Methods: Samples were collected from
peripheral blood of 50 patients before and after HSCT and at
the time of GVHD onset. Thirty patients were diagnosed as
acute leukemia/myelodysplastic syndrome, eleven as chronic
myeloid leukemia and ten with lymphomas. Seven healthy
donors were used as controls. All patients received HLA-
identical related donor graft. Except for lymphomas patients
(n¼10), who underwent non-myeloablative conditioning,
others underwent myeloablative conditioning regimens
(n¼40). Expression of FOXP3 and RORgt were assessed by
Real-Time quantitative PCR (qPCR) using the 7500 Fast Real
Time PCR System (Applied Biosystems), by Taqman method.
Comparison among groups was performed using Graphpad
Prism 5 and Mann-Withney test.
Results: Median age for the 50 analyzed patients was 36
years-old (range: 17-60), 52% were female. 50% had GVHD,
with an average onset of 39 days after HSCT for acute GVHD
(range: 12-93) and 182 days for chronic GVHD (range: 117-
266). No signiﬁcant associationwas observed between FOXP3
expression and patients with or without GVHD. On the other
hand, RORgt showed signiﬁcantly higher expression in
patients with chronic GVHD compared to samples before
HSCT (P< .0001), without GVHD (P< .0001) and acute GVHD
(P ¼ .0006). Both FOXP3 and RORgt showed signiﬁcant
statistical decreased expression in patients compared to
healthy controls, except for RORgt expression in patients
with chronic GVHD (p¼NS).
Conclusion: RORgt showed signiﬁcantly higher expression
in patients with chronic GVHD compared to samples before
HSCT, without GVHD and acute GVHD. These ﬁndings
suggest a Th17/IL-17 mediated proinﬂammatory state
involved in chronic GVHD, showing a potential target for
GVHD control.
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